NeoStem Covered by AOL’s Daily Finance Website – Vatican Investing $1 Million to Further NeoStem’s Stem Cell Development

March 7, 2011

NesoStem, Inc. was covered prominently this morning on the AOL Finance website in an article discussing the Vatican’s involvement in NeoStem’s VSEL (very small embryonic like) stem cell research. We have included the first part of the article below along with a link to the full article.

Inside Wall Street: This Tiny Stem Cell Biotech Has the Vatican’s Backing
By GENE MARCIAL Posted 7:30 AM 03/07/11 
The fiery subject of medicine based on human stem cells usually evokes roiling controversy, often generating more questions than answers. So, stem cell therapies have yet to catch on among investors — and on Wall Street. No wonder a tiny company like NeoStem (NBS), which focuses on stem cell research and its medical applications, continues to be underappreciated, if not ignored.

And yet it has attracted several big-name investors that are intrigued by some unexpected events, including the Catholic Church’s surprising embrace of NeoStem’s research and NeoStem’s foothold in China’s vast health care market. The Vatican has decided to invest $1 million in NeoStem, a biopharmaceutical company developing proprietary cellular therapies. NeoStem is aiming to become a single source for the collection, storage and manufacture of adult stem cells — rather than embryonic stem cells from aborted fetuses — for cell-based medicine and regenerative science.

What’s the Vatican’s interest in NeoStem? In particular, the Church is very interested in the company’s work on adult stem cells, and what they imply on theological and philosophical grounds.

Read More

NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development

March 7, 2011

3/7/2011 7:00 AM – PR Newswire

NEW YORK, March 7, 2011 /PRNewswire via COMTEX News Network/ —

NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce that Jason Kolbert has joined the firm as Vice President of Strategic Business Development. Jason was formerly a managing director of National Securities where he founded the firm’s research effort in emerging biotechnology companies. Jason’s coverage universe has been focused on cell therapeutic companies focused in oncology and regenerative medicine, where NeoStem was one of his covered companies.

Read More

NeoStem to Present at Cowen Healthcare Conference on March 7 and 8

March 4, 2011

NeoStem (NYSE-Amex: NBS) will present on a panel at the 31st Annual Cowen Group Health Care Conference. The panel discussion will take place on Monday, March 7, 2011 at 1 PM and Dr. Robin Smith, the Company’s Chairman and CEO, will present on Tuesday, March 8, 2011 at 10:15 AM. The Conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.

Read More

NeoStem Analyst Report: Bridging the East and the West as a One-Stop Shop for Cellular Therapy

March 2, 2011

Rodman & Renshaw has initiated coverage of NeoStem, Inc. (NYSE-Amex: NBS) with a 12-month price target of $3.00 per share.  Below is an excerpt from the report, a complete copy of which is available here.

“NeoStem is comprised of three business units, each with its own value proposition, including: 1) pharmaceutical manufacturing and sales in China ($52 MM in sales in the first 3 quarters of 2010); 2) storage and development of adult stem cells for regenerative medicine in China and in the US; and 3) third party manufacturing of cellular therapies through the acquisition of Progenitor Cell Therapy (PCT, Private). We derive our valuation for NeoStem based on a sum of the parts analysis encompassing a comparables analysis for the regenerative medicine component and a P/S multiple analysis for the Chinese pharmaceutical component. Companies developing therapeutics in the regenerative medicine space are trading at an average enterprise value (EV) of $192 MM, from which we derive a price target of $2/share for the stem cell business. The estimated value of the pharmaceutical business is $1/share after applying an average 2.6X P/S multiple to our 2011 pharmaceutical sales estimates. Based on a sum-of-the-parts methodology, we derive a 12-month target price of $3/share for NeoStem.”

Complete Report

NeoStem Analyst Report Cites a $5 Price Target

March 1, 2011

In an updated anlayst report released this morning, Maxim Group reiterates its buy rating with a 12-month price target of $5.00 for NeoStem (NYSE-Amex: NBS).  According to the report, the Company’s stem cell operations have multiple revenue generating opportunities.  Yesterday, the Company announced the planned launch of its adult stem cell banking and cord blood banking programs, which will be bundled together as “Family Plan” in the U.S.

Read More

Q&A with NeoStem Chairman and CEO Dr. Robin Smith

February 15, 2011

Dr. Robin Smith, Chairman and CEO of NeoStem (NYSE-Amex: NBS) discusses the Company’s pharmaceutical and stem cell operations in connection with its recent acquisition of Progenitor as well as expectations for the next six to twelve months.  This interview can be seen by clicking on the picture below.

NeoStem CEO Dr. Robin Smith Interviewed

February 11, 2011

NeoStem (NYSE-Amex: NBS) Chief Executive Officer, Dr. Robin Smith, is interviewed about the Company’s generic pharmaceutical and stem cell business segments.

View Video